Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | F2 | P00734 | 2/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.55 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1603596 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL306514 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL158053 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL29652034 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL362333 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL6337655 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL6335926 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL6842010 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL29040265 | 0.83 | SMN1; SMN2 (0.82) | SMN1; SMN2KMT2AMEN1KDM4EL3MBTL1 | |
| SCHEMBL11623286 | 0.83 | SMN1; SMN2 (0.82) | SMN1; SMN2KMT2AMEN1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 681 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313590-A1 | Phosphoramidite morpholino monomers towards synthesis/convergent synthesis of PMO, TMO, their chimera oligos in 5 prime to 3 prime direction | INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE (IACS) (IN) | 2025-10-09 | — | — | US | claimed |
| US-20250001384-A1 | APPARATUS AND METHODS FOR SYNTHESIZING BIOPOLYMERS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2025-01-02 | — | — | US | claimed |
| US-11912734-B2 | Solid-phase synthesis of oligonucleotides containing N6-(2-deoxy-alpha,beta-derythropentofuranosyl)-2,6-diamino-4-hydroxy-5-formamidopyrimidine (Fapy⋅dG) | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-02-27 | — | — | US | claimed |
| US-20210291137-A1 | APPARATUS AND METHODS FOR SYNTEHSIZING BIOPOLYMERS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2021-09-23 | — | — | US | claimed |
| US-20210238213-A1 | SOLID-PHASE SYNTHESIS OF OLIGONUCLEOTIDES CONTAINING N6-(2-DEOXY-ALPHA,BETA-DERYTHROPENTOFURANOSYL)-2,6-DIAMINO-4-HYDROXY-5-FORMAMIDOPYRIMIDINE (Fapy.dG) | THE JOHNS HOPKINS UNIVERSITY | 2021-08-05 | — | — | US | claimed |
| EP-2711370-B1 | METHOD FOR PRODUCING OLIGONUCLEOTIDES | AJINOMOTO KK (JP) | 2018-01-03 | — | — | EP | claimed |
| EP-2459525-B1 | ENANTIO- AND STEREO-SPECIFIC SYNTHESES OF -AMINO- - HYDROXY AMIDES | MERCK SHARP & DOHME (US) | 2017-03-01 | — | — | EP | claimed |
| US-9029528-B2 | Solution-based method of making oligonucleotides via phosphoramidite coupling | AJINOMOTO CO., INC. (JP) | 2015-05-12 | — | — | US | claimed |
| EP-2711370-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE | Ajinomoto Co., Inc. (JP) | 2014-03-26 | — | — | EP | claimed |
| US-20120296074-A1 | PRODUCTION METHOD OF OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2012-11-22 | — | — | US | claimed |
| US-20040215016-A1 | Stereospecific enrichment of heterocyclic enantiomers | R.T. ALAMO VENTURES I, LLC | 2004-10-28 | — | — | US | claimed |
| US-6809195-B1 | COMPRISES A MODIFIED PHOSPHORAMIDITE PROTOCOL IN WHICH OXIDATION AND CAPPING STEPS ARE COMBINED INTO A SINGLE STEP; INCREASED EFFICIENCY; SOLID PHASE SYNTHESIS | ISIS PHARMACEUTICALS, INC. | 2004-10-26 | — | — | US | claimed |
| US-20040198972-A1 | Processes for the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2004-10-07 | — | — | US | claimed |
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-30 | — | — | US | claimed |
| US-6730790-B2 | INCLUDING RACEMIC MONOCHLOROFLOSEQUINAN, PURIFIED ENANTIOMERS OF MONOCHLOROFLOSEQUINAN AND SULFONE DERIVATIVE OF MONOCHLOROFLOSEQUINAN | R.T. ALAMO VENTURES I. LLC | 2004-05-04 | — | — | US | claimed |
| US-6649764-B2 | Racemization of flusequinan using triphenylphosphine and 10-camphorsulfonyl-oxaziridine to form racemic mixtures | R. T. ALAMO VENTURES I, LLC | 2003-11-18 | — | — | US | claimed |
| US-6639061-B1 | Rodified oligonucleotides that bear 3'-methylene phosphonate or phosphodiester linkages between constituent monomer nucleoside units | ISIS PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | claimed |
| US-20030166677-A1 | CHLORINATED HETEROCYCLIC COMPOUNDS AND METHODS OF SYNTHESIS | R.T. ALAMO VENTURES I, LLC | 2003-09-04 | — | — | US | claimed |
| US-20030139586-A1 | C3' -methylene hydrogen phosphonate oligomers and related compounds | COOK PHILLIP DAN (US) | 2003-07-24 | — | — | US | claimed |
| US-20030120075-A1 | Stereospecific enrichment of heterocyclic enantiomers | R.T. ALAMO ADVENTURES I, LLC | 2003-06-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313590-A1 | Phosphoramidite morpholino monomers towards synthesis/convergent synthesis of PMO, TMO, their chimera oligos in 5 prime to 3 prime direction | MTAP, METTL14, M6PR | SMN1; SMN2 1256/4885KMT2A 3591/4885MEN1 1315/4885 |
| US-20030139586-A1 | C3' -methylene hydrogen phosphonate oligomers and related compounds | NT5C3B, NUDT1, MTAP | SMN1; SMN2 2377/4885KMT2A 3080/4885MEN1 659/4885 |
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | SMN1; SMN2 2454/4885KMT2A 2959/4885MEN1 3108/4885 |
| US-20030166677-A1 | CHLORINATED HETEROCYCLIC COMPOUNDS AND METHODS OF SYNTHESIS | STS, SCLY, HCCS | SMN1; SMN2 4873/4885KMT2A 1092/4885MEN1 1262/4885 |
| US-20040198972-A1 | Processes for the preparation of oligonucleotides | RNGTT, RNMT, NUDT1 | SMN1; SMN2 1547/4885KMT2A 3566/4885MEN1 3129/4885 |
| US-20210238213-A1 | SOLID-PHASE SYNTHESIS OF OLIGONUCLEOTIDES CONTAINING N6-(2-DEOXY-ALPHA,BETA-DERYTHROPENTOFURANOSYL)-2,6-DIAMINO-4-HYDROXY-5-FORMAMIDOPYRIMIDINE (Fapy.dG) | DPYD, TYMP, RNGTT | SMN1; SMN2 769/4885KMT2A 1684/4885MEN1 3043/4885 |
| US-20120296074-A1 | PRODUCTION METHOD OF OLIGONUCLEOTIDE | RNGTT, POLM, RNMT | SMN1; SMN2 938/4885KMT2A 3808/4885MEN1 2987/4885 |
| US-20040215016-A1 | Stereospecific enrichment of heterocyclic enantiomers | CBR3, POR, CBR1 | SMN1; SMN2 3953/4885KMT2A 3103/4885MEN1 3536/4885 |
| US-20030120075-A1 | Stereospecific enrichment of heterocyclic enantiomers | CBR3, POR, CBR1 | SMN1; SMN2 3953/4885KMT2A 3103/4885MEN1 3536/4885 |
| US-11912734-B2 | Solid-phase synthesis of oligonucleotides containing N6-(2-deoxy-alpha,beta-derythropentofuranosyl)-2,6-diamino-4-hydroxy-5-formamidopyrimidine (Fapy⋅dG) | DPYD, TYMP, RNGTT | SMN1; SMN2 722/4885KMT2A 1513/4885MEN1 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.